ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Nature Medicine2013Vol. 19(2), pp. 202–208
Citations Over TimeTop 1% of 2013 papers
Andrew J. Souers, Joel Johansson, Erwin R. Boghaert, Scott Ackler, Nathaniel D. Catron, Jun Chen, Brian D. Dayton, Hong Ding, Sari H. Enschede, Wayne J. Fairbrother, David C.S. Huang, S.G. Hymowitz, Sha Jin, Seong Lin Khaw, Peter Kovar, Lloyd T. Lam, Jackie Lee, Heather Maecker, Kennan C. Marsh, Kylie D. Mason, Michael J. Mitten, Paul Nimmer, Anatol Oleksijew, Chang H. Park, Cheol‐Min Park, Darren C. Phillips, Andrew W. Roberts, Deepak Sampath, John F. Seymour, Morey L. Smith, Gerard M. Sullivan, Stephen K. Tahir, Chris Tse, Michael Wendt, Xiao Yu, John Xue, Haichao Zhang, Rod Humerickhouse, Saul H. Rosenberg, Steven W. Elmore
Related Papers
- → Potential of BCL2 as a target for chronic lymphocytic leukemia treatment(2018)18 cited
- → Modified Venetoclax Dose Ramp-Up in Select High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) with Progression after B-Cell Receptor Pathway Inhibitors (BCRi)(2017)5 cited
- → VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)(2018)2 cited
- → A Study of the Safety and Efficacy of Venetoclax for Patients With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice(2019)
- → Venetoclax (Venclexta™)(2017)